Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Cancer Res. 2011 Apr 20;71(12):4314–4324. doi: 10.1158/0008-5472.CAN-11-0051

Figure 6.

Figure 6

HOXC9 is a mediator of RA action. A, Morphologic examination and cell cycle analysis of BE(2)-C cells expressing GFPsh, HOXC9sh-9 or HOXC9sh-12 that were treated with RA for 24 and 14 days, respectively. Scale bar, 100 μm. B, Proliferation assays of BE(2)-C cells expressing GFPsh, HOXC9sh-9 or HOXC9sh-12 in the presence of RA (error bars, s.d., n=3). C, Soft agar clonogenic assays of BE(2)-C cells expressing either GFPsh or HOXC9sh-9. Cells were treated with RA for 7 days before soft agar assays. D, Immunoblot analysis of cyclins in BE(2)-C cells expressing either GFPsh or HOXC9sh-9 that were treated with RA for various times. α-tubulin levels are shown as loading control.